术前新辅助化疗加手术治疗非小细胞肺癌的临床观察

Clinical observation of effect of new supplemental chemotherapy before operation plus treatment after operation on non-small-celll lung cancer patients

目的 探讨术前新辅助化疗治疗非小细胞肺癌的可行性和不良反应,同时评价其在病期下调率、提高手术切除率方面的作用。方法 从1 999年1月～2 0 0 4年9月,对我院88例非小细胞肺癌手术病例进行回顾性总结分析,32例为术前新辅助化疗病例(试验组) ,行术前化疗2～3个周期,化疗结束后3～4周手术;另56例为同期直接手术的非小细胞肺癌病例(对照组)。结果试验组化疗总有效率为68.75 % (2 2 / 32 ) ,病期下调率37.5 % (1 2 / 32 ) ;手术切除率试验组为93.1 0 % (2 7/ 2 9)、对照组为80 .36% (45/56) ;两组手术并发症和手术死亡率无显著性差异(P >0 .0 5)。结论 术前新辅助化疗安全、有效,能降低非小细胞肺癌患者的病期,提高手术切除率,同时对手术并发症率和死亡率无明显影响。

Objective To explore the feasibility of using new supplemental chemotherapy before the operation on non-small-cell lung cancer patients and its side effects, and also to evaluate its effects on shortening treatment course and increasing operation-success rate.Methods The data of 88 non-small-cell cancer inpatients admitted to our hospital between the period of January 1999 and September 2004 were retrospectively summarized and analyzed. Among them, 32 had chemotherapy before the operation (treatment group) for about 2 to 3 cycles and the operaton was performed 3～4 weeks later. Another 56 controls had operation without before-operation treatment (control group). Results The overall effective rate for the treatment group was 68.75% (22/32) and the rate of shorening treatment course was 37.5% (12/32). The success rate for operation for the treatment group was 93.10% (27/29) whereas for the control group the rate was 80.36% (45/56). There was no significant difference between the two groups regarding complication rate after operation and motality ( P > 0.05).Conclusion Chemotherapy before the operation is safe and effective. It shortens the treatment course, increases the success rate after operation and does not affect the complication rate after operation and motality.